Even more notably, they found that there were certain gene expressions that were induced by the hallucinogenic agonists but not by the non-hallucinogenic ones (Gonzalez-Maeso et al. 2003). These particular genes mainly belong to the family of early growth response (EGR) elements which are primarily known to be involved with neural growth and plasticity (Leah & Wilce 2002).
The hallucinogen-specific transcript for the protein Egr-2 showed particularly robust expression.Gene expression of neural growth and plasticity helps explain the long term benefits that have been seen with psychedelics.
The level of Egr-2 expression was proportional to the magnitude of attentional demand.Meditation has a great deal to do with attentional demand.
As neuroplasticity-based therapies emerge and begin their refinement, the two novel and central attributes they entail, that of qualitative activity-dependence and potentially permanent curative capability, parallel precisely the two key aspects of psychedelic therapy that have, over the past six decades, been a conceptual and ideological challenge for conventional medical science to address and antithetical to its economic landscape.